Evaluation of drug carrier hepatotoxicity using primary cell culture models

Kibar, Güneş; Dutta, Subhadeep; Rege, Kaushal; Usta, O. Berk

doi:10.1016/j.nano.2023.102651

Cited by 2 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current standard in drug discovery pipelines is using high-throughout, bulk screening utilizing commercially available, cryopreserved hepatocytes for studying drug metabolism and toxicity to identify hepatotoxicity early in drug development [1][2][3][4] . Primary human hepatocytes are typically isolated from transplant-rejected, non-viable livers since transplantable livers are typically allocated to a recipient.…”

Section: Introductionmentioning

confidence: 99%

Parallelized Droplet Vitrification Enables Single-Run Vitrification of the Whole Rat Liver Hepatocyte Yield

Taggart,

Tchir,

Van Dieren

et al. 2024

Preprint

View full text Add to dashboard Cite

Drug discovery pipelines rely on the availability of isolated primary hepatocytes for investigating potential hepatotoxicity prior to clinical application. These hepatocytes are typically isolated from livers rejected for transplantation and subsequently cryopreserved for later usage. The gold-standard cryopreservation technique, slow-freezing, is a labor-intensive process, with significant post-storage viability loss. In this work, we introduce parallelized droplet vitrification, a technique for high-volumetric, rapid vitrification of suspended cells. We show the utility of this technique through the single-run vitrification of the whole-rate liver hepatocyte yield, resulting in a 1600% increase in single-batch vitrification and a 500% increase in droplet generation rate compared to previous droplet vitrification approaches. Additionally, we showed that these implementations maintained improved post-preservation outcomes in primary rat hepatocytes.

show abstract

Section: Introductionmentioning

confidence: 99%

Parallelized Droplet Vitrification Enables Single-Run Vitrification of the Whole Rat Liver Hepatocyte Yield

Taggart,

Tchir,

Van Dieren

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Development of Liver Cancer Organoids: Reproducing Tumor Microenvironment and Advancing Research for Liver Cancer Treatment

Li,

Ren,

et al. 2024

Technol Cancer Res Treat

View full text Add to dashboard Cite

Liver cancer a leading cause of cancer-related deaths worldwide, yet understanding of its development mechanism remains limited, and treatment barriers present substantial challenges. Owing to the heterogeneity of tumors, traditional 2D culture models are inadequate for capturing the complexity and diversity of tumor biology and understanding of the disease. Organoids have garnered considerable attention because of their ability to self-renew and develop functional structures in vitro that closely resemble those of human organs. This review explores the history of liver organoids, their cellular origins, techniques of constructing tumor microenvironments that recapitulate liver cancer organoids, and the biological and clinical applications of liver and liver cancer organoids and explores the current challenges related to liver cancer organoid applications and potentially valuable solutions, with the aim of facilitating the construction of in vitro clinical models of liver cancer therapeutic research.

show abstract

Evaluation of drug carrier hepatotoxicity using primary cell culture models

Cited by 2 publications

References 53 publications

Parallelized Droplet Vitrification Enables Single-Run Vitrification of the Whole Rat Liver Hepatocyte Yield

Parallelized Droplet Vitrification Enables Single-Run Vitrification of the Whole Rat Liver Hepatocyte Yield

Development of Liver Cancer Organoids: Reproducing Tumor Microenvironment and Advancing Research for Liver Cancer Treatment

Contact Info

Product

Resources

About